Zhangzhou Pientzehuang Pharmaceutical Co Ltd

SHG:600436 China Drug Manufacturers - General
Market Cap
$12.86 Billion
CN¥94.37 Billion CNY
Market Cap Rank
#2643 Global
#179 in China
Share Price
CN¥156.42
Change (1 day)
+0.01%
52-Week Range
CN¥156.10 - CN¥214.25
All Time High
CN¥485.80
Categories
Companies in China Drug Manufacturers - General
About

Zhangzhou Pientzehuang Pharmaceutical., Ltd, together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. It offers Chinese medicines in various forms, including capsules, tablets, pills, syrups, and ointments, as well as health care food and functional drinks, special efficacy cosmetics, and household chemicals under the Pien Tze Huang … Read more

Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) - Net Assets

Latest net assets as of September 2025: CN¥15.04 Billion CNY

Based on the latest financial reports, Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) has net assets worth CN¥15.04 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.48 Billion) and total liabilities (CN¥2.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥15.04 Billion
% of Total Assets 86.05%
Annual Growth Rate 21.4%
5-Year Change 79.72%
10-Year Change 349.21%
Growth Volatility 50.07

Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Net Assets Trend (2000–2024)

This chart illustrates how Zhangzhou Pientzehuang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (2000–2024)

The table below shows the annual net assets of Zhangzhou Pientzehuang Pharmaceutical Co Ltd from 2000 to 2024.

Year Net Assets Change
2024-12-31 CN¥14.84 Billion +6.60%
2023-12-31 CN¥13.92 Billion +17.73%
2022-12-31 CN¥11.82 Billion +16.64%
2021-12-31 CN¥10.14 Billion +22.77%
2020-12-31 CN¥8.26 Billion +18.46%
2019-12-31 CN¥6.97 Billion +31.32%
2018-12-31 CN¥5.31 Billion +19.94%
2017-12-31 CN¥4.43 Billion +17.98%
2016-12-31 CN¥3.75 Billion +13.54%
2015-12-31 CN¥3.30 Billion +10.58%
2014-12-31 CN¥2.99 Billion +15.24%
2013-12-31 CN¥2.59 Billion +66.64%
2012-12-31 CN¥1.56 Billion +30.83%
2011-12-31 CN¥1.19 Billion +9.70%
2010-12-31 CN¥1.08 Billion +26.44%
2009-12-31 CN¥857.19 Million +13.97%
2008-12-31 CN¥752.09 Million -0.89%
2007-12-31 CN¥758.85 Million +22.18%
2006-12-31 CN¥621.09 Million +2.14%
2005-12-31 CN¥608.07 Million +12.80%
2004-12-31 CN¥539.08 Million -2.62%
2003-12-31 CN¥553.59 Million +257.60%
2002-12-31 CN¥154.81 Million +6.02%
2001-12-31 CN¥146.02 Million +3.30%
2000-12-31 CN¥141.35 Million --

Equity Component Analysis

This analysis shows how different components contribute to Zhangzhou Pientzehuang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 89473.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥10.61 Billion 74.32%
Common Stock CN¥603.32 Million 4.23%
Other Comprehensive Income CN¥2.02 Billion 14.13%
Other Components CN¥1.05 Billion 7.33%
Total Equity CN¥14.27 Billion 100.00%

Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhangzhou Pientzehuang Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
United Bankshares Inc
NASDAQ:UBSI
 		$5.35 Billion
Grifols S.A
PINK:GIFLF
 		$5.35 Billion
International Games System Co Ltd
TWO:3293
 		$5.35 Billion
Grupo Aeroportuario del Centro Norte SAB de CV
NASDAQ:OMAB
 		$5.35 Billion
DaVita HealthCare Partners Inc
NYSE:DVA
 		$5.34 Billion
Lithia Motors Inc
NYSE:LAD
 		$5.34 Billion
PNM Resources Inc
F:98P
 		$5.33 Billion
CAR Group Ltd
AU:CAR
 		$5.32 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhangzhou Pientzehuang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 13,376,325,404 to 14,271,727,825, a change of 895,402,421 (6.7%).
  • Net income of 2,977,002,489 contributed positively to equity growth.
  • Dividend payments of 2,127,271,717 reduced retained earnings.
  • Other comprehensive income increased equity by 1,939,291,244.
  • Other factors decreased equity by 1,893,619,595.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥2.98 Billion +20.86%
Dividends Paid CN¥2.13 Billion -14.91%
Other Comprehensive Income CN¥1.94 Billion +13.59%
Other Changes CN¥-1.89 Billion -13.27%
Total Change CN¥- 6.69%

Book Value vs Market Value Analysis

This analysis compares Zhangzhou Pientzehuang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 6.62x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 641.83x to 6.62x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-12-31 CN¥0.24 CN¥156.42 x
2001-12-31 CN¥0.25 CN¥156.42 x
2002-12-31 CN¥0.27 CN¥156.42 x
2003-12-31 CN¥0.94 CN¥156.42 x
2004-12-31 CN¥0.91 CN¥156.42 x
2005-12-31 CN¥1.00 CN¥156.42 x
2006-12-31 CN¥1.02 CN¥156.42 x
2007-12-31 CN¥1.25 CN¥156.42 x
2008-12-31 CN¥1.26 CN¥156.42 x
2009-12-31 CN¥1.43 CN¥156.42 x
2010-12-31 CN¥1.81 CN¥156.42 x
2011-12-31 CN¥1.98 CN¥156.42 x
2012-12-31 CN¥2.58 CN¥156.42 x
2013-12-31 CN¥4.25 CN¥156.42 x
2014-12-31 CN¥4.82 CN¥156.42 x
2015-12-31 CN¥5.21 CN¥156.42 x
2016-12-31 CN¥5.80 CN¥156.42 x
2017-12-31 CN¥6.87 CN¥156.42 x
2018-12-31 CN¥8.30 CN¥156.42 x
2019-12-31 CN¥10.99 CN¥156.42 x
2020-12-31 CN¥13.03 CN¥156.42 x
2021-12-31 CN¥16.09 CN¥156.42 x
2022-12-31 CN¥18.78 CN¥156.42 x
2023-12-31 CN¥22.19 CN¥156.42 x
2024-12-31 CN¥23.63 CN¥156.42 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhangzhou Pientzehuang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 20.86%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 27.60%
  • • Asset Turnover: 0.62x
  • • Equity Multiplier: 1.23x
  • Recent ROE (20.86%) is above the historical average (20.18%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 35.41% 27.21% 0.71x 1.83x CN¥35.92 Million
2001 35.72% 26.90% 0.72x 1.85x CN¥37.56 Million
2002 37.98% 27.73% 0.65x 2.10x CN¥43.31 Million
2003 11.14% 28.31% 0.36x 1.10x CN¥6.19 Million
2004 7.91% 16.48% 0.45x 1.06x CN¥-11.06 Million
2005 14.94% 20.63% 0.60x 1.20x CN¥28.56 Million
2006 13.88% 15.69% 0.71x 1.24x CN¥22.90 Million
2007 13.16% 16.05% 0.61x 1.34x CN¥22.88 Million
2008 19.40% 21.68% 0.61x 1.47x CN¥68.25 Million
2009 15.72% 18.66% 0.54x 1.56x CN¥47.20 Million
2010 18.50% 22.38% 0.60x 1.38x CN¥89.18 Million
2011 22.14% 24.95% 0.65x 1.36x CN¥139.74 Million
2012 23.23% 29.76% 0.52x 1.49x CN¥198.51 Million
2013 17.15% 30.79% 0.43x 1.30x CN¥179.14 Million
2014 15.09% 30.18% 0.40x 1.25x CN¥147.98 Million
2015 14.79% 24.75% 0.47x 1.29x CN¥151.14 Million
2016 15.35% 23.22% 0.46x 1.44x CN¥186.79 Million
2017 19.51% 21.73% 0.66x 1.37x CN¥393.41 Million
2018 22.78% 23.98% 0.72x 1.33x CN¥641.28 Million
2019 20.73% 24.02% 0.65x 1.33x CN¥711.24 Million
2020 21.26% 25.67% 0.64x 1.30x CN¥885.30 Million
2021 25.06% 30.32% 0.64x 1.29x CN¥1.46 Billion
2022 21.82% 28.44% 0.60x 1.29x CN¥1.34 Billion
2023 20.91% 27.81% 0.59x 1.28x CN¥1.46 Billion
2024 20.86% 27.60% 0.62x 1.23x CN¥1.55 Billion

Industry Comparison

This section compares Zhangzhou Pientzehuang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $1,443,093,618
  • Average return on equity (ROE) among peers: -7.88%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) CN¥15.04 Billion 35.41% 0.16x $5.34 Billion
Zhejiang Int'L Group Co Ltd (000411) $177.19 Million 13.55% 0.63x $201.14 Million
Zhejiang Zhenyuan Share Co Ltd (000705) $280.61 Million 7.70% 0.99x $310.45 Million
Hunan Jingfeng Pharmaceutical (000908) $638.18 Million -181.03% 3.22x $202.85 Million
Hubei Guangji Pharmaceutical Co Ltd (000952) $477.68 Million 3.28% 0.64x $234.89 Million
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) $361.29 Million 26.02% 0.32x $146.91 Million
Yifan Xinfu Pharmaceutical Co Ltd (002019) $9.15 Billion 2.09% 0.37x $1.03 Billion
Guangdong Jiaying Pharmaceutical Co Ltd (002198) $278.08 Million 2.72% 0.13x $459.10 Million
Chongqing Lummy Pharmaceutical (300006) $107.91 Million 22.70% 0.99x $476.38 Million
Zhejiang Jolly Pharmaceutical Co Ltd (300181) $1.44 Billion 5.91% 0.29x $1.19 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) $1.53 Billion 18.22% 0.05x $893.48 Million